pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›TOFACITINIB CITRATE
drug · small molecule
save

TOFACITINIB CITRATE

Phase 1updated 3mo ago
by $SIGY Sigyn Therapeutics, Inc.🔗 ChEMBL
Phase 1
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval222 co-mentions · 60 sources
  • drugXELJANZ XR213 co-mentions · 60 sources
  • drugXELJANZ213 co-mentions · 60 sources
  • drugtofacitinib ER111 co-mentions · 60 sources
  • drugtofacitinib citrate ER111 co-mentions · 60 sources
  • drugtofacitinib111 co-mentions · 60 sources
  • tagSmall Molecule111 co-mentions · 60 sources
  • companyAjanta Pharma Ltd7 co-mentions · 7 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and psoriatic arthritis and 4 investigational indications.

targets

Janus Kinase (JAK)

all catalysts(0)

nothing on the calendar yet

Trials studying TOFACITINIB CITRATE

  • phase2A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritisnot yet recruitingn=156
  • phase2Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitiscompletedn=40
  • phase2Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.completedn=180

News(0)

no news has mentioned this drug yet

brand
TOFACITINIB CITRATE
trade names
Xeljanz, Xeljanz xr
generic
TOFACITINIB CITRATE
MOA
Janus Kinase (JAK) inhibitor
indication
Atopic Dermatitis (Atopic Eczema)
phase
phase_1
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?